Abstract
The functional characteristics of the a1-adrenoceptor subtypes in human resistance arteries are still not clear. We recently reported that the a1A-adrenoceptor predominantly mediates contraction to norepinephrine in human skeletal muscle resistance arteries. In this study we extended these investigations to human subcutaneous resistance arteries. Arterial segments were isolated from the inguinal subcutaneous fat and mounted on a small vessel wire myograph. Potencies of agonists and antagonists were examined.N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulphonamide (A-61603) was found to be 10- and 54-fold more potent than norepinephrine and phenylephrine, respectively. Brimonidine (UK 14304) evoked significantly smaller contractile responses than norepinephrine and phenylephrine, showing the presence of a small population of a2-adrenoceptors in these arteries, and this was confirmed by the studies with selective a1- and a2-adrenoceptor antagonists prazosin and (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13a-decahydro-3-methoxyl-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine (RS 79948). Prazosin, 5-methyl-urapidil, and 2-[2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB 4101) shifted the potency of norepinephrine concentration dependently giving pA2 values of 9.4, 8.9, and 10.1, respectively, showing the presence of the a1A-subtype in these arteries. Pretreatment with 1 and 10 µM chloroethylclonidine did not affect the potency of and maximum responses to norepinephrine, ruling out the presence of the a1B-subtype in these arteries. 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY 7378, 10 and 100 nM) did not affect the potency of norepinephrine but a small shift was observed by 1 µM BMY 7378, giving a pKB value of 7.1, much less than that reported for the a1D-subtype. These results suggest the predominant involvement of a1A-adrenoceptor in the contractile responses to norepinephrine in these arteries. The physiological role of this subtype in the maintenance of peripheral arterial resistance is yet to be confirmed.
| Original language | English |
|---|---|
| Pages (from-to) | 729-734 |
| Number of pages | 6 |
| Journal | Journal of Pharmacology and Experimental Therapeutics |
| Volume | 299 |
| Issue number | 2 |
| Publication status | Published - 1 Nov 2001 |
Fingerprint
Keywords
- human subcutaneous resistance arteries
- a1-adrenoceptor subtypes
Cite this
}
Functional characterization of a1-adrenoceptor subtypes in human subcutaneous resistance arteries. / Jarajapu, Yagna P.R.; Johnston, Fiona; Berry, Colin; Renwick, Andrew; McGrath, John C.; MacDonald, Allan; Hillier, Chris.
In: Journal of Pharmacology and Experimental Therapeutics, Vol. 299, No. 2, 01.11.2001, p. 729-734.Research output: Contribution to journal › Article
TY - JOUR
T1 - Functional characterization of a1-adrenoceptor subtypes in human subcutaneous resistance arteries
AU - Jarajapu, Yagna P.R.
AU - Johnston, Fiona
AU - Berry, Colin
AU - Renwick, Andrew
AU - McGrath, John C.
AU - MacDonald, Allan
AU - Hillier, Chris
N1 - <p>Originally published in: Journal of Pharmacology and Experimental Therapeutics (2001), 299 (2), pp.729-734.</p>
PY - 2001/11/1
Y1 - 2001/11/1
N2 - The functional characteristics of the a1-adrenoceptor subtypes in human resistance arteries are still not clear. We recently reported that the a1A-adrenoceptor predominantly mediates contraction to norepinephrine in human skeletal muscle resistance arteries. In this study we extended these investigations to human subcutaneous resistance arteries. Arterial segments were isolated from the inguinal subcutaneous fat and mounted on a small vessel wire myograph. Potencies of agonists and antagonists were examined.N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulphonamide (A-61603) was found to be 10- and 54-fold more potent than norepinephrine and phenylephrine, respectively. Brimonidine (UK 14304) evoked significantly smaller contractile responses than norepinephrine and phenylephrine, showing the presence of a small population of a2-adrenoceptors in these arteries, and this was confirmed by the studies with selective a1- and a2-adrenoceptor antagonists prazosin and (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13a-decahydro-3-methoxyl-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine (RS 79948). Prazosin, 5-methyl-urapidil, and 2-[2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB 4101) shifted the potency of norepinephrine concentration dependently giving pA2 values of 9.4, 8.9, and 10.1, respectively, showing the presence of the a1A-subtype in these arteries. Pretreatment with 1 and 10 µM chloroethylclonidine did not affect the potency of and maximum responses to norepinephrine, ruling out the presence of the a1B-subtype in these arteries. 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY 7378, 10 and 100 nM) did not affect the potency of norepinephrine but a small shift was observed by 1 µM BMY 7378, giving a pKB value of 7.1, much less than that reported for the a1D-subtype. These results suggest the predominant involvement of a1A-adrenoceptor in the contractile responses to norepinephrine in these arteries. The physiological role of this subtype in the maintenance of peripheral arterial resistance is yet to be confirmed.
AB - The functional characteristics of the a1-adrenoceptor subtypes in human resistance arteries are still not clear. We recently reported that the a1A-adrenoceptor predominantly mediates contraction to norepinephrine in human skeletal muscle resistance arteries. In this study we extended these investigations to human subcutaneous resistance arteries. Arterial segments were isolated from the inguinal subcutaneous fat and mounted on a small vessel wire myograph. Potencies of agonists and antagonists were examined.N-[5-(4,5-dihydro-1H-imidazol-2yl)-2-hydroxy-5,6,7,8-tetrahydronaphthalen-1-yl]methanesulphonamide (A-61603) was found to be 10- and 54-fold more potent than norepinephrine and phenylephrine, respectively. Brimonidine (UK 14304) evoked significantly smaller contractile responses than norepinephrine and phenylephrine, showing the presence of a small population of a2-adrenoceptors in these arteries, and this was confirmed by the studies with selective a1- and a2-adrenoceptor antagonists prazosin and (8aR,12aS,13aS)-5,8,8a,9,10,11,12,12a,13a-decahydro-3-methoxyl-12-(ethylsulphonyl)-6H-isoquino[2,1-g][1,6]-naphthyridine (RS 79948). Prazosin, 5-methyl-urapidil, and 2-[2,6-dimethoxyphenoxyethyl]aminomethyl)-1,4-benzodioxane (WB 4101) shifted the potency of norepinephrine concentration dependently giving pA2 values of 9.4, 8.9, and 10.1, respectively, showing the presence of the a1A-subtype in these arteries. Pretreatment with 1 and 10 µM chloroethylclonidine did not affect the potency of and maximum responses to norepinephrine, ruling out the presence of the a1B-subtype in these arteries. 8-[2-[4-(2-methoxyphenyl)-1-piperazinyl]ethyl]-8-azaspiro[4.5]decane-7,9-dione (BMY 7378, 10 and 100 nM) did not affect the potency of norepinephrine but a small shift was observed by 1 µM BMY 7378, giving a pKB value of 7.1, much less than that reported for the a1D-subtype. These results suggest the predominant involvement of a1A-adrenoceptor in the contractile responses to norepinephrine in these arteries. The physiological role of this subtype in the maintenance of peripheral arterial resistance is yet to be confirmed.
KW - human subcutaneous resistance arteries
KW - a1-adrenoceptor subtypes
M3 - Article
VL - 299
SP - 729
EP - 734
JO - Journal of Pharmacology and Experimental Therapeutics
JF - Journal of Pharmacology and Experimental Therapeutics
SN - 0022-3565
IS - 2
ER -